摘要
OBJECTIVE To discover a small molecule targeting ULK1-modulated cell death of triple negative breast cancer and exploreits potential mechanisms.METHODS ULK1 expression was analyzed by The Cancer Genome Atlas(TCGA)analysis and tissue microarray(TMA)analysis.ULK1agonist was designed by using in silico screening,as well as modified by chemical synthesis and screened by kinase and anti-proliferative activities.The amino acid residues that key to the activation site of LYN-1604 were determined by site-directed mutagenesis,as well as in vitro kinase assay and ADP-Glo kinase assay.The mechanisms of LYN-1604 induced cell death were investigated by fluorescence microscope,western blotting,flow cytometry analysis,immunocytochemistry,as well as si RNA and GFP-m RFP-LC3 plasmid transfections.Potential ULK1 interactors were discovered by performing comparative microarray analysis and the therapeutic effect of LYN-1604 was assessed by xenograft breast cancer mouse model.RESULTS We found that ULK1 was remarkably downregulated in breast cancer tissue samples,especial y in triple negative breast cancer(TNBC).32 candidate smal molecules were synthesized,and we discovered a small molecule named LYN-1604 as the best candidate ULK1agonist.Additionally,we identified that three amino acid residues(LYS50,LEU53 and TYR89)were key to the activation site of LYN-1604 and ULK1.Subsequently,we demonstrated that LYN-1604 could induce autophagy-associated cell death via ULK complex(ULK1-m ATG13-FIP200-ATG101)in MDA-MB-231 cells.We also found that LYN-1604 induced cell death involved in ATF3,RAD21 and caspase 3,accompanied with autophagy and apoptosis.Moreover,we demonstrated that LYN-1604 had a good therapeutic potential on TNBC by targeting ULK1-modulated cell death in vivo.CONCLUSION We discovered a small molecule(LYN-1604)has therapeutic potential by targeting ULK1-modulated cell death associated with autophagy and apoptosis of TNBC in vitro and in vivo,which could be utilized as a new anti-TNBC drug candidate.
OBJECTIVE To discover a small molecule targeting ULKl-modulated cell death of triple negative breast cancer and exploreJts potential mechanisms. METHODS ULK1 expression was analyzed by The Cancer Genome Atlas （TCGA） analysis and tissue microarray （TMA） analysis. ULK1 agonist was designed by using in silico screening, as well as modified by chemical synthesis and screened by kinase and anti-proliferative activities. The amino acid residues that key to the activation site of LYN-1604 were determined by site-directed mutagenesis, as well as in vitro kinase assay and ADP-GIo kinase assay. The mechanisms of LYN-1604 induced cell death were investigated by fluores- cence microscope, western blotting, flow cytometry analysis, immunocytochemistry, as well as siRNA and GFP-mRFP-LC3 plasmid transfections. Potential ULK1 interactors were discovered by performing comparative microarray analysis and the therapeutic effect of LYN-1604 was assessed by xenograft breast cancer mouse model. RESULTS We found that ULK1 was remarkably downregulated in breast cancer tissue samples, especially in triple negative breast cancer （TNBC）. 32 candidate small molecules were synthesized, and we discovered a small molecule named LYN-1604 as the best candidate ULK1 agonist. Additionally, we identified that three amino acid residues （LYS50, LEU53 and TYR89） were key to the activation site of LYN-1604 and ULKI. Subsequently, we demonstrated that LYN-1604 could induce autophagy-associated cell death via ULK complex （ULK1-mATG13-FIP200-ATG101） in MDA- MB-231 cells. We also found that LYN-1604 induced cell death involved in ATF3, RAD21 and caspase 3, accompanied with autophagy and apoptosis. Moreover, we demonstrated that LYN-1604 had a good therapeutic potential on TNBC by targeting ULKl-modulated cell death in vivo. CONCLUSION We discovered a small molecule （LYN-1604） has therapeutic potential by targeting ULKl-modulated cell death associated with autophagy and apoptosis of TNBC in vitro and in vivo, which could be utilized as a new anti-TNBC drug candidate.
出处
《中国药理学与毒理学杂志》
CAS
CSCD
北大核心
2017年第10期957-958,共2页
Chinese Journal of Pharmacology and Toxicology
基金
supported by National Natural Science Foundation of China(81402496,81673455and 81602627)
China Postdoctoral Special Science Foundation(2017T100704)
China Postdoctoral Science Foundation(2015M580794)
作者简介
Corresponding author： Bo LIU, Tel： 15708469925, E-mail：liubo2400@ 163.com
